Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients.
Najla AljaberiEnas GhulamEmily A SmithermanLeslie FavierDana M H DykesLara A Danziger-IsakovRebecca C BradyJennifer HugginsPublished in: The Journal of rheumatology (2020)
Results of this study support the benefit of HBV screening in immunosuppressed patients. Beginning at age 11 years, most patients lacked serologic immunity to HBV. Seroconversion for most patients 11-18 years occurred after 1 booster vaccine. Thus, for immunocompromised patients without recent HBV serologic data, obtaining the HBV serology beginning at age 11 years might be considered. Those 18 years and older were least likely to seroconvert after 1 booster, indicating that they may benefit from receiving the 3-dose HBV vaccine series.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- hepatitis b virus
- prognostic factors
- rheumatoid arthritis
- machine learning
- intensive care unit
- young adults
- systemic lupus erythematosus
- liver failure
- coronavirus disease
- acute respiratory distress syndrome
- disease activity
- mechanical ventilation
- patient reported